Nova Mentis Life Science Corp.
NMLSF
Price:
$0.005
Market Cap:
$1.01M
Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Men...[Read more]
Industry
Biotechnology
IPO Date
2008-06-27
Stock Exchange
PNK
Ticker
NMLSF
The ROE as of September 2024 (TTM) for Nova Mentis Life Science Corp. (NMLSF) is 73.69%
According to Nova Mentis Life Science Corp.’s latest financial reports and current stock price. The company's current ROE is 73.69%. This represents a change of 267.25% compared to the average of 20.06% of the last 4 quarters.
Nova Mentis Life Science Corp. (NMLSF) Historical ROE (quarterly & annually)
How has NMLSF ROE performed in the past?
The mean historical ROE of Nova Mentis Life Science Corp. over the last ten years is -931.36%. The current 73.69% ROE has changed -107.91% with respect to the historical average. Over the past ten years (40 quarters), NMLSF's ROE was at its highest in in the September 2015 quarter at 1.08%. The ROE was at its lowest in in the December 2022 quarter at -2586.17%.
Average
-931.36%
Median
-331.70%
Minimum
-5964.31%
Maximum
151.05%
Nova Mentis Life Science Corp. (NMLSF) ROE by Quarter and Year
Discovering the peaks and valleys of Nova Mentis Life Science Corp. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 7.80%
Maximum Annual ROE = 151.05%
Minimum Annual Increase = -102.53%
Minimum Annual ROE = -5964.31%
| Year | ROE | Change |
|---|---|---|
| 2023 | 151.05% | -102.53% |
| 2022 | -5964.31% | 919.97% |
| 2021 | -584.75% | 18.44% |
| 2020 | -493.70% | 2.11% |
| 2019 | -22.33% | -54.73% |
| 2018 | -49.34% | -18.93% |
| 2017 | -60.86% | -80.84% |
| 2016 | -317.59% | -8.16% |
| 2015 | -345.80% | -78.73% |
| 2014 | -1625.97% | 7.80% |
Nova Mentis Life Science Corp. (NMLSF) Average ROE
How has NMLSF ROE performed in the past?
The current ROE of Nova Mentis Life Science Corp. (NMLSF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2132.67%
5-year avg
-1382.81%
10-year avg
-931.36%
Nova Mentis Life Science Corp. (NMLSF) ROE vs. Peers
How is NMLSF’s ROE compared to its peers?
Nova Mentis Life Science Corp.’s ROE is less than Awakn Life Sciences Corp. (292.48%), less than PsyBio Therapeutics Corp. (59.41%), greater than HAVN Life Sciences Inc. (0%), less than Tryp Therapeutics Inc. (131.45%), less than Wesana Health Holdings Inc. (0%), less than BioVaxys Technology Corp. (242.19%), less than GH Research PLC (328.15%), greater than Algernon Pharmaceuticals Inc. (-16.39%), greater than AXIM Biotechnologies, Inc. (-213.50%), less than Mind Cure Health Inc. (54.15%), greater than Surrozen, Inc. (-10.08%), greater than Jasper Therapeutics, Inc. (-178.66%), greater than Revelation Biosciences, Inc. (-64.68%), greater than Protagenic Therapeutics, Inc. (-243.91%), greater than Sino Biopharmaceutical Limited (-238.37%), less than ZIVO Bioscience, Inc. (1.69%), less than Cyteir Therapeutics, Inc. (673.84%), greater than Eledon Pharmaceuticals, Inc. (-23.13%), greater than null (-124.74%),
| Company | ROE | Market cap |
|---|---|---|
| 292.48% | $2.42M | |
| 59.41% | $308.90K | |
| 0% | $326.45K | |
| 131.45% | $5.42M | |
| 0% | $230.87K | |
| 242.19% | $10.79M | |
| 328.15% | $415.70M | |
| -16.39% | $1.54M | |
| -213.50% | $1.81M | |
| 54.15% | $86.53M | |
| -10.08% | $17.64M | |
| -178.66% | $346.97M | |
| -64.68% | $4.40M | |
| -243.91% | $2.80M | |
| -238.37% | $7.33B | |
| 1.69% | $47.13M | |
| 673.84% | $108.71M | |
| -23.13% | $99.14M | |
| -124.74% | $0 |
Build a custom stock screener for Nova Mentis Life Science Corp. (NMLSF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nova Mentis Life Science Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Nova Mentis Life Science Corp. (NMLSF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Nova Mentis Life Science Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Nova Mentis Life Science Corp.'s ROE?
How is the ROE calculated for Nova Mentis Life Science Corp. (NMLSF)?
What is the highest ROE for Nova Mentis Life Science Corp. (NMLSF)?
What is the 3-year average ROE for Nova Mentis Life Science Corp. (NMLSF)?
What is the 5-year average ROE for Nova Mentis Life Science Corp. (NMLSF)?
How does the current ROE for Nova Mentis Life Science Corp. (NMLSF) compare to its historical average?